Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)

被引：0
|
作者：
Majid, Oneeb [1 ]
Xiao, Jianjun Alan [2 ]
Sahmoud, Tarek [2 ]
Yasuda, Sanae [3 ]
Cantagallo, Lisa [2 ]
Hamilton, Erika P. [4 ]
Pluard, Timothy [5 ]
Juric, Dejan [6 ]
Gualberto, Antonio [2 ]
Husseiin, Ziad [1 ]
机构：
[1] Eisai, Hatfield, Herts, England
[2] H3 Biomed, Cambridge, MA USA
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] St Lukes Canc Inst, Kansas City, MO USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS12-15
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
  • [32] Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
    Nayar, Utthara
    Cohen, Ofir
    Kapstad, Christian
    Cuoco, Michael S.
    Waks, Adrienne G.
    Wander, Seth A.
    Painter, Corrie
    Freeman, Samuel
    Persky, Nicole S.
    Marini, Lori
    Helvie, Karla
    Oliver, Nelly
    Rozenblatt-Rosen, Orit
    Ma, Cynthia X.
    Regev, Aviv
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    NATURE GENETICS, 2019, 51 (02) : 207 - +
  • [33] Mechanisms of resistance to estrogen receptor modulators in ER+/HER2-advanced breast cancer
    Zhang, Jin
    Wang, Qianying
    Wang, Qing
    Cao, Jiangran
    Sun, Jiafu
    Zhu, Zhengmao
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2020, 77 (04) : 559 - 572
  • [34] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).
    Martin, Miguel
    Lim, Elgene
    Mac Gregor, Mariana Chavez
    Shivhare, Mahesh
    Ross, Graham
    Patre, Monika
    Roncoroni, Laura
    Louka, Maria
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [36] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [37] Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study
    Rugo, Hope S.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Bardia, Aditya
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Kaklamani, Virginia G.
    Romero, Paula Munoz
    Vallespir, Bartomeu Piza
    Wasserman, Tomer
    Theall, Kathy Puyana
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
    Basaran, Gul A.
    Twelves, Chris
    Dieras, Veronique
    Cortes, Javier
    Awada, Ahmad
    CANCER TREATMENT REVIEWS, 2018, 63 : 144 - 155
  • [39] A novel scoring system based on the clinical and genomic variables to predict the early relapse in estrogen receptor-positive/HER2-negative (ER+/HER2-) breast cancer
    Lin, Caijin
    Wu, Jiayi
    Ding, Shuning
    Andriani, Lisa
    Chen, Weilin
    Liu, Deyue
    Zhu, Li
    CANCER RESEARCH, 2020, 80 (04)
  • [40] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Lin, Nancy U.
    Awada, Ahmad
    Gil, Eva Ciruelos
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    CANCER RESEARCH, 2024, 84 (07)
12345